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Abstract
Background
The number of people living with HIV on antiretroviral treatment (ART) in Myanmar has
been increasing rapidly in recent years. This study aimed to estimate rates of virological fail-
ure on first-line ART and switching to second-line ART due to treatment failure at the Inte-
grated HIV Care program (IHC).
Methods
Routinely collected data of all adolescent and adult patients living with HIV who were initi-
ated on first-line ART at IHC between 2005 and 2015 were retrospectively analyzed. The
cumulative hazard of virological failure on first-line ART and switching to second-line ART
were estimated. Crude and adjusted hazard ratios were calculated using the Cox regression
model to identify risk factors associated with the two outcomes.
Results
Of 23,248 adults and adolescents, 7,888 (34%) were tested for HIV viral load. The incidence
rate of virological failure among those tested was 3.2 per 100 person-years follow-up and
the rate of switching to second-line ART among all patients was 1.4 per 100 person-years
follow-up. Factors associated with virological failure included: being adolescent; being lost
to follow-up at least once; having WHO stage 3 and 4 at ART initiation; and having taken
first-line ART elsewhere before coming to IHC. Of the 1032 patients who met virological fail-
ure criteria, 762 (74%) switched to second-line ART.
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Conclusions
We found high rates of virological failure among one third of patients in the cohort who were
tested for viral load. Of those failing virologically on first-line ART, about one quarter were
not switched to second-line ART. Routine viral load monitoring, especially for those identi-
fied as having a higher risk of treatment failure, should be considered in this setting to detect
all patients failing on first-line ART. Strategies also need to be put in place to prevent treat-
ment failure and to treat more of those patients who are actually failing.
Introduction
Antiretroviral therapy (ART) has been available free-of-charge for more than 10 years in the
public and private health sectors in Myanmar. By the end of 2015, 106,490 patients were on
ART. This number accounted for 55% of the estimated People Living with Human Immuno-
deficiency Virus (PLHIV) in Myanmar. The National AIDS Program (NAP) has been rapidly
scaling up ART in the country and aims to achieve universal access in a few years to reduce
HIV-related morbidity and mortality [1]. With this rapid scaling up, it is also important to sus-
tain treatment success with undetectable viral loads in patients on first-line ART. Otherwise,
failing on first-line regimens can lead to a complicated, less tolerable and more expensive sec-
ond-line ART regimen with fewer drug options if drug related toxicities develop. Therefore, it
is important clinically and programmatically to learn more about the rate of first-line treat-
ment failure, the rate of switching to a second-line ART regimen and to identify which patients
are at risk in order to develop strategies to prevent developing of further failure cases.
Studies conducted in Asia and elsewhere have shown different rates (ranging from 1.1–4.5
per 100 person-years) and proportions (ranging from 11–28%) of patients failing on treatment
[2–6], partly because treatment failure was diagnosed differently (clinically, immunologically
or virologically) across these studies. The rate of patients switching to second-line ART has
ranged from 2.2 to 3.3 per 100 person-years [7–11]. Studies have shown that different demo-
graphic, clinical and treatment factors were associated with treatment failure on first-line ART
and switching to second-line ART [4,12–14]. However, there is a lack of published data in
Myanmar on first-line ART failure and the rate of switching to a second-line regimen, both of
which are important indicators for the Myanmar HIV/AIDS Program to assess.
The Integrated HIV Care (IHC) program, supported by The Union in Myanmar, has been
providing treatment and care to PLHIV from all regions of the country since 2005. By 2015,
nearly 30,000 patients were on ART and all patients’ data had been routinely collected in an
electronic database. In this study, we retrospectively analysed the rates of treatment failure and
switching to second-line ART in adolescent and adult patients receiving first-line ART in the
IHC program. We also determined risk factors associated with these two outcomes.
Methods
Study design and study population
This study was a retrospective cohort analysis of all adolescent and adult PLHIV who were ini-
tiated on first-line ART under IHC care between 1st February 2005 and 1st July 2015. Adoles-
cent (aged 10 to 19 years inclusive) and adult (older than 19 years) age groups are defined
according to the WHO definition of age groups and populations in the 2013 HIV Consolidated
guidelines [15]. We included ART naive patients as well as non-naïve patients who were
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previously on first-line ART at a private and government clinic/hospital. The following
patients were excluded: i) women who were initiated on ART under the prevention of mother
to child transmission (PMTCT) program; ii) patients who were already on second-line ART at
the time of enrollment; and iii) patients whose duration of follow up was less than 6 months
after ART had been initiated at the IHC.
Study setting
Integrated HIV Care (IHC) program. Of a total of 15 regions in Myanmar, the IHC pro-
gram has been operating in the Mandalay, Sagaing, Magway, Shan and Yangon regions through
33 sites (ART centres and decentralized sites) in collaboration with the National AIDS Control
Program (NAP) since 2005. Patients attending IHC sites come from all 15 regions of Myanmar.
The evolution of the IHC program has been described elsewhere [16]. Decentralized ART sites
under the IHC program started in 2010 for patients who were identified as being stable on ART
at ART centres and willing to receive treatment at decentralized sites. Health care providers at
ART centres include specialist physicians, HIV clinicians and nurses. Decentralized sites do not
initiate PLHIV on ART and do not have physicians able to care for ill and complicated patients.
The latter are referred back to the ART centres for specialist care and advice.
Patient follow-up and care at IHC sites. The HIV management and ART provision at
IHC sites follow the NAP and WHO treatment guidelines [15, 17]. Chronic HIV care includ-
ing antiretroviral drugs and laboratory investigations are provided free of charge in all IHC
sites. After ART initiation, patients are monitored for their treatment response clinically and
immunologically. After having been on ART for six months or longer with increasing CD4 cell
counts and good adherence to treatment, if a patient develops a new or recurrent WHO clini-
cal stage 3 or 4 condition, clinical failure is suspected. Immunological failure is suspected if the
CD4 cell count falls to the baseline or below or stays persistently below 100cells/μl after six
months on ART. These clinical or immunological suspected failures are not routinely docu-
mented in the IHC database. The program follows a targeted viral load testing strategy as rou-
tine viral load monitoring is not available, but only some of the patients who have clinical and
immunological failure on first-line ART are referred for HIV viral load testing by clinicians.
Viral load testing using an automated c1000 RealTime PCR system (Bio-Rad Sciences, Hercu-
les, California, USA and HIV Generic Charge Virale, Biocentric, Bandol, France) has been
available in the Public Health Laboratory in Mandalay. This laboratory is under the manage-
ment of the Ministry of Health, Myanmar, which has been supported by the Union since late
2012. Prior to this and since 2009, the samples were sent to an outside laboratory for viral load
testing using Rotor-Gene Real-Time Analysis (PG. Biotech HIV detection kit). Before 2009,
there was no viral load testing in the country and patients’ treatment was monitored clinically
or immunologically.
Although reference is made to National and/or WHO HIV treatment guidelines, the diag-
nostic criteria of failure on first-line ART and the decision to switch to second-line ART differ
from clinician to clinician. The routine practice is that if the viral load is detectable but is lower
than the cut-off point for virological failure, the viral load test is repeated after 3 months of
intensive adherence counselling. If the patient’s viral load becomes undetectable, or detectable
but lower than the virological failure cut-off point, the first-line ART regimen is continued. If
the patient’s viral load is higher than the cut-off point, a protease inhibitor based second-line
ART regimen which is available in the program is prescribed. The virological failure cut-off
point of the HIV viral load was 5000 copies/mL up to March 2015, and thereafter the threshold
was reduced to 1000 copies/mL in line with recommendations in the WHO guidelines. Sec-
ond-line ART (protease inhibitors) was only available from the end of 2008. Before this time,
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patients who were diagnosed as having ART failure on either clinical or immunological
grounds were continued on first-line ART.
Study variables
Outcome variables. The two outcome variables were virological failure while on first-line
ART and switching to second-line ART. We defined virological failure as a viral load result
greater than 5000 copies/mL before March 2015 and greater than 1000 copies/mL after March
2015. Switching to second-line ART was defined as a patient being switched to a protease
inhibitor based ART regimen from a nucleoside reverse-transcriptase inhibitor and non-
nucleoside reverse-transcriptase inhibitor based ART regimens. For those who switched to
second-line ART, we also recorded the reason for switching as documented in the database.
Exposure variables. Exposure variables included: gender; age at ART initiation (groups
included adolescents (10 to 19 years) [18] and adults (>19 years)); marital, employment and
literacy status; HIV transmission risk factors; availability of a care taker (someone who comes
along with the patient for clinic visit and helps patient for taking drugs at home, usually the
patient’ family or close friend) when ART was initiated; baseline CD4 cell count and WHO clin-
ical stage; first-line ART regimens at enrolment; history of ART before coming to IHC; baseline
hepatitis B and C status; type of current IHC site (ART centre or decentralized site), number
of times the patient had been documented as “lost to follow-up” from care; number of times
the first-line ART regimen had been modified. First-line ART regimens that were modified in-
cluded: tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) + efavirenz (EFV); stavudine
(d4T) + 3TC+ nevirapine (NVP); D4T+3TC+EFV; zidovudine (AZT) + 3TC+EFV; d4T+3TC+
NVP; AZT+3TC+NVP; and TDF+3TC+NVP. We considered CD4 cell count measurements
taken within three months either before or after ART initiation as the baseline CD4 cell count.
Data source and data extraction
Data was extracted without the patient’s name and address from the electronic database of the
IHC program which is routinely updated by data staff.
Data analysis
Time to virological failure on first-line ART and switch to second-line ART, and the cumulative
hazard of first-line failure and switching to second-line ART were estimatedusing Nelson-Aalen
methods. Crude and adjusted hazard ratios with 95% confidence intervals were calculated for
predictor variables to assess any association with virological failure and switching to second-line
ART using the Cox proportional-hazards model. Predictor variables with a P-value of<0.2 in
the univariate analysis were included in a multivariate regression model after excluding patients
with missing data. A P-value of less than 0.05 was considered statistically significant. Probability
of virological failure and switching to second-line ART were plotted.
The time to virological failure was defined as the time between the date of starting first-line
ART and the date of the first diagnosis of virological failure. The time to switching to second-
line ART was defined as the time between the date of starting first-line ART and the date of
switching to second-line ART. For patients who died or were lost-to-follow-up or transferred
out, the date of last appointment before the event was considered as the censor date. If a patient
was lost to follow-up from the program for more than three months and then came back to the
program, we considered that he/she was ‘lost to follow-up at-least once’. If a patient was lost to
follow-up from care more than once, the date of the most recent lost to follow-up date was
used as the censor date. For patients retained in care and without any event, 31st December
2015 was considered the censor date. Statistical analyses were performed using Stata 12 [19].
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Ethics considerations
The study was based on a retrospective analysis of routinely collected data. Ethics approval
from The Union Ethics Advisory Group (Paris, France) and permission from the National
HIV/AIDS program, Department of Public Health, Ministry of Health and Sports, Myanmar
were received for this study. Unique codes were used and all patient identifier information was
removed before the analysis.
Results
Characteristics of the cohort
There were 23,248 adolescent and adult patients started on ART in the IHC program who met
inclusion criteria of this study. They were followed up for a total of 70,689 person-years.
Females accounted for 42% of the cohort and the median (Interquartile range) age at ART ini-
tiation was 36 (31–42) years. Adolescents constituted 3% of the cohort. The majority (55%) of
the cohort was married. A few patients disclosed that they belonged to one of the key popula-
tions: men who had sex with men (1.4%); commercial sex workers (0.2%); and injection drug
users (4%). Most of the patients (84%) were recorded as having a care taker. Overall, 15% of
the patients had taken ART at private clinics, government hospitals and/or National AIDS pro-
gram clinics before coming to the IHC sites. The most common starting ART regimens were:
TDF + 3TC + EFV (36.5%); d4T+ 3TC + NVP (21.8%); and d4T+3TC+EFV (19.0%). The
baseline prevalence of hepatitis B and C was 8% and 6.4% respectively. At the end of the study
period, 30% of patients were receiving care at the decentralized ART sites and 13% of the
cohort was recorded as being lost to follow-up at least one time. Half of the patients experi-
enced ART regimen modification at least once during the study period (Table 1).
Virological failure
Incidence rate of virological failure. There were 7,888 (34% of the whole cohort) patients
who were assessed for viral load, and of these 1032 (13%) met the virological failure criteria.
The incidence rate of virological failure after first-line ART amongst those tested was 3.2 per
100 person-years of follow-up (PYFU). The cumulative hazard of virological failure at 5 years
and 10 years after starting ART amongst those tested was 17% and 22% respectively (Fig 1).
Stratified by duration on first-line ART, the incidence rate of failure in patients who were
on ART for less than one year, between one and two years and for more than two years was
65.9, 26.3 and 2.0 per 100 PYFU respectively.
Factors associated with virological failure. After adjusting the covariates, adolescent age
at enrollment, patients with baseline WHO clinical stage 3 and 4 disease, patients with severe
and moderate immune suppression with CD4 count less than 350 cells/μl, those who had
taken ART at a private clinic before enrollment, and those who had a history of loss to follow-
up from the care at least one time were all found to be at significantly higher risk of virological
failure compared with reference groups. Patients who were divorced or separated from their
spouses, who were receiving ART at decentralized sites and whose first-line ART regimen was
modified more than one time had a significantly lower risk of failure. Gender, literacy, employ-
ment status, not having a care taker, the initial ART regimen and co-infection with Hepatitis B
or C had no significant association with failure. (Table 2)
Switching to second-line ART
Incidence rate of switching to second-line ART. Of 23248 patients, 931 (4%) patients
switched to second-line ART with a rate of 1.35 per 100 PYFU. The cumulative hazard of
Virologic failure and switching to second-line ART
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Table 1. Socio-demographic and clinical characteristics of patients who received first-line ART regimen at the Integrated HIV Care program, Myan-
mar, between 2005 and 2015.
Baseline socio-demographic characteristics Number %
All patients 23,248 100
Gender Male 13,446 57.8
Female 9,802 42.2
Age group (years) 10–19 633 2.7
20 22,615 97.3
Marital status Single 4,840 20.8
Married 12,697 54.6
Widowed 4,069 17.5
Divorced/Separate 1,349 5.8
Missing data 294 1.3
Employment status Employed 16,619 71.5
Not employed 6,192 26.6
Missing data 438 1.9
Literacy Literate 20,800 89.5
Illiterate 2,214 9.5
Missing data 235 1.0
Transmission risk Heterosexual 19,329 83.1
Men having sex with men 334 1.4
Sex work 46 0.2
Injecting drug use 941 4.0
Blood transfusion 747 3.2
Mother to child 488 2.1
Missing 1,364 5.9
Care taker Available 19,567 84.2
Not available 3,681 15.8
Region of ART site Mandalay 12,226 52.6
Sagaing 2,255 9.7
Magway 2,047 8.8
Shan 2,924 12.6
Yangon 3,796 16.3
Baseline clinical characteristics
WHO staging 1 and 2 8,715 37.5
3 and 4 14,533 62.5
CD4 count (cells/μl) <100 7,647 32.9
100–350 11,807 50.8
>350 2,028 8.7
Missing data 1,766 7.6
ART delivery site before enrolment Private 2,372 10.2
Public 783 3.4
Unknown site 295 1.3
Naïve 19,798 85.2
ART regimen TDF+3TC+EFV 8,494 36.5
AZT+3TC+EFV 2365 10.2
d4T+3TC+EFV 4419 19.0
d4T+3TC+NVP 5069 21.8
AZT+3TC+NVP 2762 11.9
(Continued )
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switching to second-line ART at 5 years of taking first-line ART was 7% and at 10 years was
12% (Fig 2). Of 931 patients who switched to second-line ART, 88% were switched due to
treatment failure, 1.3% due to toxicity and 10% had no recorded information.
Stratified by duration on first-line ART, the incidence of switching to second-line ART in
patients who were on ART for less than one year, between one and two years and more than
two years was 4.49, 3.91 and 0.89 per 100 PYFU respectively.
Factors associated with switching to second-line ART. After adjusting the covariates,
adolescent age at enrollment, patients with baseline WHO clinical stage 3 and 4 disease, those
with severe and moderate immune suppression with CD4 counts less than 350 cells/μl, those
who had taken ART at private and public clinics before enrollment, those whose first ART regi-
mens were not TDF+3TC+EFV and those who had a history of loss to follow-up from the care
at least one time were significantly associated with a higher risk of switching to second-line ART.
Patients who were receiving ART at a decentralized site and whose first-line ART regimen
were modified more than one time were at significantly lower risk of switching to second-line
ART. Patients’ gender, marital, employment and literacy status, having no care taker at initia-
tion of ART and co-infection with hepatitis B or C had no significant association with chang-
ing to second-line treatment. (Table 3.)
Gap between virological failure and switching to second-line ART
Of 1032 patients who had a detectable viral load and met the criteria for treatment failure, 762
(74%) switched to second-line ART. Of 270 patients who did not switch to second-line ART
during study period, 103 (37%) died or were recorded as lost to follow up and 159 (60%) were
Table 1. (Continued)
Baseline socio-demographic characteristics Number %
TDF+3TC+NVP 13 0.1
Missing 8 0.0
Hepatitis B Positive 1,922 8.0
Negative 19,597 84.0
Missing data 1,729 7.0
Hepatitis C Positive 1,480 6.4
Negative 20,034 86.2
Missing data 1,734 7.5
Follow-up clinical characteristics
Current ART site ART center 16,123 69.4
Decentralized site 7,125 30.6
Loss to follow up (number of times) 0 20,305 87.3
1 2572 11.1
>1 371 1.6
Duration on ART (months) 6–12 3,574 15.4
12–24 5,008 21.5
>24 14,666 63.1
ART regimen modification (number of times) 0 11,511 49.5
1–3 11,141 47.9
>3 596 2.6
ART = antiretroviral therapy; WHO = World Health Organization; d4T = stavudine, AZT = zidovudine, 3TC = lamivudine, EFV = efavirenz, NVP = nevirapine,
ABC = abacavir, TDF = tenofovir
doi:10.1371/journal.pone.0171780.t001
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on first-line ART and still in care at the end of the study period. The gaps between virological
failure and switching to second-line ART were highest in adolescents, those whose risk of HIV
transmission was from the mother, those who were initiated with TDF+3TC+EFV regimens
and those who had never modified their first-line ART regimen (Tables 1 and 2).
Discussion
This study of adolescent and adult patients on ART in Myanmar provides important findings.
First, the overall rate of treatment failure was 3.2 per 100 PYFU and the rate of switching to
second-line ART was 1.35 per 100 PYFU. The 10 year cumulative incidence of failing on first-
line ART was 22% and of switching to a second-line protease inhibitor based ART regimen
was 12%. These findings highlight the gap between people failing on treatment and people
switching treatment due to treatment failure. The rate of switching to second-line ART might
be higher if all patients on first-line treatment can get access to viral load testing. These
Fig 1. Nelson Aalen curve showing the cumulative hazard of virological failure in patients on first-line ART initiated at Integrated HIV Care
program, Myanmar, between 2005 and 2015.
doi:10.1371/journal.pone.0171780.g001
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Table 2. Rates and predictors of virological failure in patients initiated on first-line ART in the Integrated HIV and Care Program in Myanmar
between 2005 and 2015.
Socio-demographic factors Number of virological
failures
Rate per 100
PYFUa
Hazard Ratio
(95% CIb)
p-value Adjusted Hazard
Ratio (95% CIb)
p-value
Total 1032 3.2
Gender Male 668 3.5 1.3(1.2–1.4) <0.001 1.1(0.9–1.2) 0.56
Female 364 2.7 refd ref
Age group (years) Adolescent (10–
19)
64 10.4 3.3(2.5–4.2) <0.001 4.2(2.0–8.8) <0.001
Adult (20) 968 3.1 ref ref
Marital status Single 286 4.1 ref ref
Married 542 3.1 0.8(0.7–0.9) <0.001 0.9(0.8–1.1) 0.41
Widowed 152 2.6 0.6(0.5–0.8) <0.001 0.8(0.7–1.1) 0.23
Divorced/
Separate
32 2.2 0.5(0.4–0.8) <0.01 0.6(0.4–0.9) <0.05
Missing 20 5.7 1.4(0.9–2.2) 0.17
Employment status Employed 738 3.2 ref
Not employed 284 3.4 1.1(0.9–1.2) 0.35
Literacy Literate 922 3.2 ref
Illiterate 100 3.6 1.1(0.9–1.4) 0.21
Transmission risk Heterosexual 846 3.1 ref ref
Men sex with
men
25 5.5 1.8(1.2–2.6) <0.01 1.5(0.9–2.4) 0.06
Sex work 2 4.1 1.3(0.3–5.4) 0.68 3.1(0.8–12.3) 0.11
Injecting drug
use
30 2.9 1.0(0.7–1.4) 0.80 0.9(0.6–1.4) 0.67
Blood
transfusion
36 3.4 1.1(0.8–1.5) 0.56 0.9(0.7–1.4) 0.85
Mother to child 49 10.1 3.2(2.4–4.3) <0.001 0.5(0.2–1.0) 0.06
Care taker Available 807 3.4 ref ref
Not available 225 2.8 0.8(0.7–0.9) <0.05 1.0(0.8–1.2) 0.70
Baseline clinical factors
WHO clinical stage 1 and 2 271 2.8 ref ref
3 and 4 761 3.4 1.3(1.1–1.5) <0.01 1.3(1.1–1.6) <0.01
CD4 count (cells/μl) <100 460 3.8 2.0(1.5–2.6) <0.001 2.6(1.8–3.7) <0.001
100–350 408 2.7 1.5(1.1–1.9) <0.05 2.0(1.4–2.8) <0.001
>350 36 1.9 ref ref
ART before enrolled Private 255 5.5 2.0(1.7–2.3) <0.001 2.2(1.8–2.5) <0.001
Public 55 2.9 1.03(0.8–1.4) 0.80 1.1(0.7–1.5) 0.77
unknown site 17 4.6 1.6(0.9–2.5) 0.07 1.7(0.9–3.1) 0.07
Naïve 705 2.8 ref ref
ART regimen TDF+3TC+EFV 143 15.8 ref ref
Other regimenc 885 2.8 0.2(0.1–0.2) <0.001 0.9(0.7–1.1) 0.29
Missing 4 20.2 1.2(0.5–3.3) 0.69
Hepatitis B Negative 892 3.1 ref ref
Positive 90 4.3 1.4(1.2–1.7) <0.01 0.9(0.7–1.3) 0.56
Hepatitis C Negative 932 3.2 ref
Positive 50 2.8 0.8(.7–1.2) 0.33
Follow-up clinical factors
Current ART site ART center 738 4.4 ref ref
(Continued )
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findings are also of value in estimating the needs of second-line ART in the country and in
planning the necessary care for patients who are on second-line ART.
Second, this study shows that the virological failure rate in Myanmar is higher than the
virological failure rate reported in other studies: from China (12% failed after 2 years on ART)
[20], from South Africa (failure rate of 4.5 per 100 PYFU)[6], from Cambodia (11.6% failed
with a viral load cut-off of 400 copies/mL and 4.3% with a viral load cut-off of 30,000 copies/
mL)[2] and from a pooled estimate for the Asia region from a recent systematic review [21].
However, comparisons of rates of failure across different studies and countries are difficult
because of different viral load cut-off points, duration of time on ART and follow-up periods.
Third, the rate of switching to second-line ART in this study (1.3 per 100 PYFU) is compa-
rable to results of some other studies, especially from programs which have no routine viral
load monitoring. However, the incidence of switching to second-line ART in our study was
lower than that reported from other programs which do have routine viral load monitoring.
[5,7,8] These findings strongly suggest that there is a possibility of under-diagnosis of treat-
ment failure in our program and there may be substantial numbers of patients with virological
failure who need to switch to second-line ART. Therefore, routine viral load monitoring
should be considered in all program settings if resources permit [22].
We found that the incidence of virological failure and switching to second-line ART was
highest in the first year after ART had been initiated at the IHC. This finding contrasts with
other reported findings that showed that viral suppression was usually higher in the first two
years after treatment compared to later years when ART failure started to increase [8,23]. One
of the likely reason might be due to the fact that access to viral load testing was significantly
higher among recent cohorts of patients (6–12 months) compared to others. Hence the recent
cohort of patients were more likely to get diagnosed as virological failure earlier and contribut-
ing less number of person-years of follow-up. Whereas older cohorts were less likely to get
viral load tested and contributing to more person-years of follow-up. Another reasons for this
discrepancy might be selection bias as half of the patients in the group categorized as “one year
treatment duration (6–12 months)” in our study had taken ART previously at private clinics
Table 2. (Continued)
Socio-demographic factors Number of virological
failures
Rate per 100
PYFUa
Hazard Ratio
(95% CIb)
p-value Adjusted Hazard
Ratio (95% CIb)
p-value
Decentralized
site
294 1.9 0.4(0.4–0.5) <0.001 0.5(0.4–0.6) <0.001
Loss to follow up (number of
times)
0 807 3.0 ref ref
1 174 3.7 1.3(1.1–1.5) <0.01 1.4(1.1–1.6) <0.01
>1 51 7.3 2.6(1.9–3.4) <0.01 2.0(1.5–2.8) <0.001
ART regimen modification
(number of times)
0 493 15.8 ref ref
1–3 504 1.9 0.1(0.1–0.1) <0.001 0.1(0.1–0.2) <0.001
>3 35 1.7 0.1(0.1–0.1) <0.001 0.1(0.1–0.2) <0.001
Predictor variables with significant associations (p<0.2) in univariate analysis were adjusted in multivariate analysis. Missing data were excluded in the
multivariate model. ART = antiretroviral therapy; WHO = World Health Organization; d4T = stavudine, AZT = zidovudine, 3TC = lamivudine,
EFV = efavirenz, NVP = nevirapine, ABC = abacavir, TDF = tenofovir disoproxil fumarate
a person-year follow up
b confidence interval
c other regimen included d4T+3TC+EFV, d4T+3TC+NVP, AZT+3TC+NVP, AZT+3TC+EFV, TDF+3TC+NVP, ABC+3TC+NVP/EFV
d ref = reference group
doi:10.1371/journal.pone.0171780.t002
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before coming to IHC. More in-depth analysis and research is needed to understand the asso-
ciation between duration on ART and the treatment success in this population. Nonetheless,
this finding is still useful to inform the program about the need for careful monitoring of
patient adherence and response to treatment in the initial two years of first-line ART.
Adolescents were at higher risk of treatment failure and of switching to second-line ART
compared with adults. Despite the higher switching rate, the adolescent group still had a large
gap in being able to access second-line ART when they failed on first-line ART. This merits
further research and also suggests that health care providers need to consider customized ser-
vices for this age group with respect to drug adherence and clinical care due to the challenges
that they are known to face [24,25].
Starting ART at an advanced stage of illness or immunosuppression was associated with
treatment failure, a finding that is in line with many other studies [2,6,13]. Patients who had
taken ART at private clinics or other facilities before being enrolled to IHC also had a higher
risk of ART failure, maybe because they received a non-standardized regimen or suboptimal
Fig 2. Nelson Aalen curve showing the cumulative hazard of switching to second-line ART after starting first-line ART at the Integrated HIV Care
program, Myanmar, between 2005 and 2015
doi:10.1371/journal.pone.0171780.g002
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Table 3. Rates and predictors of switching to second-line ART in patients on first-line ART, Integrated HIV and Care Program, Myanmar, between
2005 and 2015.
Socio-demographic
factors
Number of switches to
second-line ART (%)
Rate per 100
PYFUa
Hazard Ratio
(95% CIb)
p-value Adjusted Hazard
Ratio (95% CIb)
p-value
Total 931 1.35
Gender Male 584 1.47 1.2(1.1–1.4) <0.01 1.0(0.8–1.1) 0.68
Female 347 1.19 refd ref
Age group (years) Adolescent (10–
19)
46 2.78 2.2(1.6–2.9) <0.001 2.7(1.1–6.4) <0.05
Adult (20) 885 1.32 ref ref
Marital status Single 241 1.66 ref ref
Married 503 1.34 0.8(0.7–0.9) <0.01 0.9(0.8–1.0) 0.44
Widowed 142 1.15 0.7(0.6–0.8) <0.001 0.8(0.6–1.0) 0.09
Divorced/
Separate
32 0.93 0.6(0.4–0.8) <0.01 0.7(0.5–1.0) 0.08
Employment status Employed 651 1.33 ref
Not employed 272 1.46 1.1(0.9–1.3) 0.21
Literacy Literate 834 1.36 ref
Illiterate 90 1.33 1.0(0.8–1.2) 0.72
Transmission risk Heterosexual 769 1.32 ref ref
Men sex with
men
20 2.05 1.6(1.0–2.4) 0.05 1.2(0.7–2.0) 0.44
Sex work 1 0.78 0.6(0.1–4.3) 0.61 0.6(0.1–4.4) 0.63
Injecting drug
use
28 1.26 1(0.7–1.5) 0.87 1.0(0.7–1.5) 0.95
Blood
transfusion
36 1.67 1.3(0.9–1.8) 0.15 1.1(0.8–1.6) 0.47
Mother to child 38 2.93 2.3(1.7–3.2) <0.001 0.8(0.3–1.9) 0.58
Care taker Available 717 1.33 ref
Not available 214 1.45 1(0.9–1.2) .75
Baseline clinical factors
WHO staging I/II 235 1.00 ref ref
III/IV 696 1.54 1.5(1.3–1.8) <0.001 1.5(1.3–1.8) <0.001
CD4 count (cells/μl) <100 415 1.81 2.9(2.1–4.0) <0.001 3.0(2.0–4.4) <0.001
100–350 377 1.11 1.8(1.3–2.5) <0.001 5.5(3.7–8.1) <0.001
>350 32 0.64 ref)
ART before enrolled Private 256 3.33 3(2.6–3.5) <0.001 4.2(3.6–5.0) <0.001
Public 57 1.65 1.4(1.1–1.9) 0.01 1.7(1.2–2.5) <0.01
Unknown site 15 1.84 1.7(1.0–2.9) <0.05 1.9(1.0–3.5) <0.05
Naïve 603 1.06 ref ref
ART regimen TDF+3TC+EFV 133 0.93 ref ref
Other regimenc 795 1.45 1.2(1.0–1.4) 0.08 3.4(2.7–4.3) <0.001
Hepatitis B Negative 787 1.33 ref ref
Positive 94 1.68 1.3(1.0–1.6) <0.05 1.3(1.0–1.6) <0.05
Hepatitis C Negative 841 1.38 ref
Positive 41 1.08 0.8(0.6–1.1) 0.21
Follow-up clinical factors
Current ART site ART center 666 1.62 ref
Decentralized
site
265 0.96 0.5(0.5–0.6) <0.001 0.5(0.4–0.6) <0.001
(Continued )
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therapy in the other facilities. Thus, it is worth considering the need for viral load or resistance
testing before starting on a standardized regimen at the IHC clinic in this group [26].
There is published evidence that patients who miss a clinic visit, who are not 100% retained
in care or who have poor drug adherence are at higher risk of virological failure [13,27,28]. We
observed that being lost to follow up at least once was associated with treatment failure in this
study which indicates that a patient lost from care is a proxy for suboptimal adherence and
interruption of therapy. This group of patients needs to be further assessed by social workers
or counsellors in terms of understanding why they are lost to care and appropriate support
should be provided.
We also found that people who started with TDF+3TC+EFV were less likely to switch to a
second-line regimen. This may be due to the fact that TDF+3TC+EFV can be taken as a once-
daily regimen. In addition, this regimen can be less toxic and therefore better tolerated than
other regimens. Hence, patients who started with TDF+3TC+EFV regimen may have better
adherence and be less likely to fail.
The rate of virological failure and switching to second-line was not significantly different
between patients who had a caretaker at the first visit and those who did not have a caretaker.
As having a caretaker is one of the criteria necessary to start ART in this program, we need to
reconsider the care taker requirement which may not be necessary for starting ART.
One of the most important findings was that not all virologically failing patients were
switched to protease inhibitor based second-line ART, especially the group of adolescents. We
cannot certain that all patients with virological failure need to switch to alternate treatment
regimens. Because there is no drug resistance testing available in our setting to inform whether
the detectable viral load is due to resistance to first-line ART or non-adherence to medication.
However, the evidence from other studies shows that about 90% of the patients with detectable
viral load are already resistant to first-line ART in these circumstances where there is no rou-
tine system for doing viral load monitoring [29].
Another important observation from this study is that one in three of those who did not
switch to second-line ART died or were lost to follow-up. Previous studies have shown that a
delay in treatment switching when required is associated with high mortality and lost to
Table 3. (Continued)
Socio-demographic
factors
Number of switches to
second-line ART (%)
Rate per 100
PYFUa
Hazard Ratio
(95% CIb)
p-value Adjusted Hazard
Ratio (95% CIb)
p-value
Lost to follow-up (number of
times)
0 739 1.28 ref ref
1 156 1.65 1.2(1.0–1.5) <0.05 1.3(1.0–1.6) <0.01
>1 36 2.27 1.7(1.2–2.4) <0.01 1.5(1.0–2.1) 0.04
ART regimen modification
(number of times)
0 499 2.27 ref ref
1–3 404 0.93 0.3(0.3–0.3) <0.001 0.2(0.2–0.2) <0.001
>3 28 0.88 0.3(0.2–0.4) <0.001 0.1(0.1–0.2) <0.001
Predictor variables with significant associations (p<0.2) in univariate analysis were adjusted in multivariate analysis. Missing data were excluded in the
multivariate model. ART = antiretroviral therapy; WHO = World Health Organization; d4T = stavudine, AZT = zidovudine, 3TC = lamivudine,
EFV = efavirenz, NVP = nevirapine, ABC = abacavir, TDF = tenofovir disoproxil fumarate
a person-year follow up
b confidence interval
c other regimen included d4T+3TC+EFV, d4T+3TC+NVP, AZT+3TC+NVP, AZT+3TC+EFV, TDF+3TC+NVP, ABC+3TC+NVP/EFV
d ref = reference group
doi:10.1371/journal.pone.0171780.t003
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follow-up [5,9,10]. Hence, it is important for the program to follow-up those patients who
have not switched but are still under care.
One of the strengths of this study is the relatively large sample size with individual patient
follow-up time data. The study was also conducted within the routine program setting which
reflects ground reality. Because of the existing mechanisms of data validity, the data are rela-
tively good and reliable. We also reported this study according to STROBE guidelines [30].
However, there were several limitations to this study. First, we excluded: 1) women who
entered the program for PMTCT interventions as the database does not fully capture their start-
ing ART regimens; 2) 40 patient records with missing ART start date and/or the type of regimen;
3) 6778 patients with follow-up less than 6 months. Second, although clinical and immunological
failure was used as a proxy for virological failure by clinicians for deciding to switch to second-
line ART or to refer for a HIV viral load test, there was no data about how many patients had
clinical and immunological failure in this program. Moreover, not all viral load measurements
were captured because some patients died or were lost to follow-up after testing and before the
results were dispatched to be recorded in the patient’s file. This may affect the rate of failure
observed in this study. Third, as this study was an analysis of a large cohort followed up for 10
years, the viral load cut off points to declare virological failure differed over these years. Fourth,
there was no viral load testing or available second-line ART from 2005 to 2008 and patients who
experienced virological failure during these four years were not be able to be diagnosed in the
program or captured in this database. Fifth, there was no information about whether patients
with virological failure were developing resistance to their current ART or were having viral
blips which are important factors to decide upon when therapy switches are being considered
[31]. Sixth, there were missing data and there may also have been data recording and data entry
errors, as our analysis was based on routinely collected program data. Finally, we could not
answer the reasons for why some of those who failed did not switch to second-line ART.
Conclusions
From this observational study of a large cohort of patients on ART in Myanmar, we found a
high incidence of virological failure amongst patients who were tested for viral load. There was
also a gap in switching to second-line ART in patients who had failed on first-line ART, espe-
cially amongst adolescents. The true incidence of virological failure and the exact number of
patients who need to switch to second-line ART cannot be determined due to scarcity of viral
load testing and lack of capacity to do drug resistance testing. Routine testing of viral load, as
WHO has recommended, in this setting can help to diagnose patients who fail on their treat-
ment especially those who are adolescents, who have been lost to follow-up at least once, with
advanced stage at ART initiation and who have taken ART elsewhere before coming to IHC.
Further research needs to be considered to better understand those who are at high risk of
treatment failure. This will help the development of strategies to prevent treatment failure and
to plan for resources to ensure that those actually failing can be properly treated.
Supporting information
S1 Dataset. First-line ART failure and switching to second-line ART, Myanmar.
(DTA)
Acknowledgments
We are grateful to The Department for International Development (DFID), UK for funding
the Global Operational Research Fellowship Programme at the International Union Against
Virologic failure and switching to second-line ART
PLOS ONE | DOI:10.1371/journal.pone.0171780 February 9, 2017 14 / 17
Tuberculosis and Lung Disease (The Union), Paris, France in which Nang Thu Thu Kyaw,
Myo Min Oo, Khine Wut Yee Kyaw [authors] works as operational research fellows and for
funding this open access publication. We are also grateful to the patients receiving care at the
Integrated HIV Care Program and health care providers and administrative staff at the Union
office and Ministry of Health and Sports in Myanmar for providing treatments and care to
patients and collecting this data.
Author contributions
Conceptualization: NTTK ADH AMVK MMO KWYK.
Data curation: NTTK ADH AMVK MMO.
Formal analysis: NTTK ADH AMVK MMO.
Funding acquisition: ADH AMVK.
Investigation: NTTK ADH AMVK MMO KWYK.
Methodology: NTTK ADH AMVK MMO KWYK.
Project administration: NTTK ADH.
Resources: NTTK ADH AMVK MMO KWYK TW TKA.
Software: NTTK ADH AMVK MMO.
Supervision: NTTK ADH AMVK.
Validation: NTTK ADH AMVK.
Visualization: NTTK ADH AMVK MMO.
Writing – original draft: NTTK ADH AMVK.
Writing – review & editing: NTTK ADH AMVK MMO KWYK TW TKA ACM HNO.
References
1. National AIDS Programme. National Strategic Plan on HIV and AIDS Myanmar 2016–2020. Ministry of
Health and Sports Myanmar; 2016.
2. Ferradini L, Laureillard D, Prak N, Ngeth C, Fernandez M, Pinoges L, et al. Positive outcomes of
HAART at 24 months in HIV-infected patients in Cambodia. AIDS. 2007; 21(17):2293–2301. doi: 10.
1097/QAD.0b013e32828cc8b7 PMID: 18090277
3. Boender TS, Sigaloff KCE, McMahon JH, Kiertiburanakul S, Jordan MR, Barcarolo J, Ford N,et al.
Long-term Virological Outcomes of First-Line Antiretroviral Therapy for HIV-1 in Low- and Middle-
Income Countries: A Systematic Review and Meta-analysis. Clin Infect Dis 2015; 61(9):1453–61. doi:
10.1093/cid/civ556 PMID: 26157050
4. Shet A, Kumarasamy N, Poongulali S, Shastri S, Kumar DS, Rewari BB, et al. Longitudinal Analysis of
Adherence to First-Line Antiretroviral Therapy: Evidence of Treatment Sustainability from an Indian HIV
Cohort. Curr HIV Res. 2016; 14(1).
5. Jespersen S, Hønge BL, Medina C, da Silva Te´ D, Correira FG, Laursen AL, et al. Lack of awareness of
treatment failure among HIV-1-infected patients in Guinea-Bissau—a retrospective cohort study. J Int
AIDS Soc. 2015; 18:20243. doi: 10.7448/IAS.18.1.20243 PMID: 26426197
6. Fox MP, Cutsem GV, Giddy J, Maskew M, Keiser O, Prozesky H, et al. Rates and predictors of failure of
first-line antiretroviral therapy and switch to second-line ART in South Africa. J Acquir Immune Defic
Syndr. 2012; 60(4):428–437. doi: 10.1097/QAI.0b013e3182557785 PMID: 22433846
7. Haas AD, Keiser O, Balestre E, Brown S, Bissagnene E, Chimbetete C, et al. Monitoring and Switching
of First-line Antiretroviral Therapy in sub-Saharan Africa: Collaborative Analysis of Adult Treatment
Cohorts. Lancet HIV. 2015; 2(7):e271–e278. doi: 10.1016/S2352-3018(15)00087-9 PMID: 26423252
Virologic failure and switching to second-line ART
PLOS ONE | DOI:10.1371/journal.pone.0171780 February 9, 2017 15 / 17
8. ART-LINC of IeDEA Study Group. Switching to second-line antiretroviral therapy in resource-limited
settings: comparison of programmes with and without viral load monitoring. AIDS. 2009; 23(14):1867–
1874. doi: 10.1097/QAD.0b013e32832e05b2 PMID: 19531928
9. Petersen ML, Tran L, Geng EH, Reynolds S, Kambugu A, Wood R, et al. Delayed switch of antiretroviral
therapy after virologic failure associated with elevated mortality among HIV-infected adults in Africa.
AIDS. 2014; 28(14):2097–2107. doi: 10.1097/QAD.0000000000000349 PMID: 24977440
10. Charles M, Leger PD, Severe P, Guiteau C, Apollon A, Gulick RM, et al. Virologic, clinical and immuno-
logic responses following failure of first-line antiretroviral therapy in Haiti. J Int AIDS Soc. 2012; 15
(2):17375. doi: 10.7448/IAS.15.2.17375 PMID: 22713258
11. Landier J, Akonde A, Pizzocolo C, Haidara I, Drabo M, Pizarro L, et al. Switch to second-line ART in
West African routine care: incidence and reasons for switching. AIDS Care. 2011 Jan; 23(1):75–8. doi:
10.1080/09540121.2010.498867 PMID: 21218279
12. Hassan AS, Nabwera HM, Mwaringa SM, Obonyo C, Sanders EL, de Wit TFR, et al. HIV-1 virologic fail-
ure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in
coastal Kenya: a cross-sectional study. AIDS Res Ther. 2014; 11(1):9. doi: 10.1186/1742-6405-11-9
PMID: 24456757
13. Rupe´rez M, Pou C, Maculuve S, Cedeno S, Luis L, Rodriguez, et al. Determinants of virological failure
and antiretroviral drug resistance in Mozambique. J Antimicrob Chemother. 2015; 70(9):2639–2647.
doi: 10.1093/jac/dkv143 PMID: 26084302
14. Bacha T, Tilahun B, Worku A. Predictors of treatment failure and time to detection and switching in HIV-
infected Ethiopian children receiving first line anti-retroviral therapy. BMC Infectious Diseases. 2012
Aug 24; 12(1):197.
15. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and
preventing HIV infection [Internet]. WHO; 2013 [cited 2014 Mar 6]. Available from: http://www.who.int/
hiv/pub/guidelines/arv2013/en/
16. Thida A, Tun STT, Zaw SKK, Lover AA, Cavailler P, Chunn J, et al. Retention and risk factors for attri-
tion in a large public health ART program in Myanmar: a retrospective cohort analysis. PLoS ONE.
2014; 9(9):e108615. doi: 10.1371/journal.pone.0108615 PMID: 25268903
17. National AIDS Program. Guideline for the clinical managemnet of HIV infection in adults and adolens-
cents in Myanmar. Department of Health, Ministry of Health Myanmar; 2011.
18. Adolescent Health Committee, Canadian Paediatric Society. Age limits and adolescents. Paediatr Child
Health. 2003 Nov; 8(9):577. PMID: 20019831
19. Stata [Statistical software]. Version12.1. StataCorp. College Station, TX: StataCorp LP; 2009.
20. Ma Y, Zhao D, Yu L, Bulterys M, Robinson ML, Zhao Y, et al. Predictors of virologic failure in HIV-1-
infected adults receiving first-line antiretroviral therapy in 8 provinces in China. Clin Infect Dis. 2010; 50
(2):264–271. doi: 10.1086/649215 PMID: 20017637
21. Renaud-The´ry F, Duncombe C, Kerr S, Thierry S, Perriens J. Adult antiretroviral therapy in resource
limited settings: a systematic review of first-line failure and attrition rate [Internet]. [cited 2015 Nov 13].
Available from: http://www.who.int/hiv/topics/treatment/First_Line_ART_failure_RLS_metanalysis.pdf
22. Harries AD, Zachariah R, van Oosterhout JJ, Reid SD, Hosseinipour MC, Chirwa Z, et al. Diagnosis
and management of antiretroviral-therapy failure in resource-limited settings in sub-Saharan Africa:
challenges and perspectives. Lancet Infect Dis. 2010; 10(1):60–65. doi: 10.1016/S1473-3099(09)
70321-4 PMID: 20129150
23. Bila DCA, Boullosa LT, Vubil AS Mabunda NJ, Abreu CM, Ismael N, Jani IV, et al. Trends in Prevalence
of HIV-1 Drug Resistance in a Public Clinic in Maputo, Mozambique. PLoS ONE. 2015; 10(7):
e0130580. doi: 10.1371/journal.pone.0130580 PMID: 26151752
24. Jobanputra K, Parker LA, Azih C, Okello V, Maphalala G, Kershberger B, et al. Factors associated with
virological failure and suppression after enhanced adherence counselling, in children, adolescents and
adults on antiretroviral therapy for HIV in Swaziland. PLoS ONE. 2015; 10(2):e0116144. doi: 10.1371/
journal.pone.0116144 PMID: 25695494
25. Agwu AL, Fairlie L. Antiretroviral treatment, management challenges and outcomes in perinatally HIV-
infected adolescents. J Int AIDS Soc. 2013; 16:18579. doi: 10.7448/IAS.16.1.18579 PMID: 23782477
26. Trotter AB, Hong SY, Srikantiah P, Abeyewickreme I, Bertagnolio S, Jordan MR. Systematic review of
HIV drug resistance in Southeast Asia. AIDS Rev. 2013 Sep; 15(3):162–70. PMID: 24002200
27. Ochieng W, Kitawi RC, Nzomo TJ, Mwatelah RS, Kimulwo MJ, Ochieng DJ, et al. Correlates of Adher-
ence and Treatment Failure Among Kenyan Patients on Long-term Highly Active Antiretroviral Therapy.
J Acquir Immune Defic Syndr. 2015; 69(2):e49–56. doi: 10.1097/QAI.0000000000000580 PMID:
26009836
Virologic failure and switching to second-line ART
PLOS ONE | DOI:10.1371/journal.pone.0171780 February 9, 2017 16 / 17
28. Crawford TN. Poor retention in care one-year after viral suppression: a significant predictor of viral
rebound. AIDS Care. 2014; 26(11):1393–1399. doi: 10.1080/09540121.2014.920076 PMID: 24848440
29. Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, von Wyl V, Yerly S, et al. Virological monitoring and resis-
tance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO
guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 2009; 9(7):409–417. doi: 10.
1016/S1473-3099(09)70136-7 PMID: 19555900
30. Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke LP, et al. The Strengthen-
ing the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for
reporting observational studies. Lancet 2007; 370: 1453–57. doi: 10.1016/S0140-6736(07)61602-X
PMID: 18064739
31. Kanapathipillai R, McManus H, Kamarulzaman A, Lim PL, Templeton DJ, Law M, et al. The significance
of HIV “blips” in resource-limited settings: is it the same? analysis of the treat Asia HIV Observational
Database (TAHOD) and the Australian HIV Observational Database (AHOD). PLoS ONE. 2014; 9(2):
e86122. doi: 10.1371/journal.pone.0086122 PMID: 24516527
Virologic failure and switching to second-line ART
PLOS ONE | DOI:10.1371/journal.pone.0171780 February 9, 2017 17 / 17
